HC Wainwright Issues Negative Estimate for UNCY Earnings
HC Wainwright has lowered its Q4 2025 earnings per share estimate for Unicycive Therapeutics to ($0.35) from $0.50, maintaining a "Buy" rating with a $22.00 price target. The stock has a "Moderate Buy" consensus with a $34.33 target. Unicycive's stock rose 6.4% to $5.67, with a market cap of $121.85 million. Institutional investors own 40.42% of the stock. The company develops therapies for kidney diseases, including Renazorb and UNI 494.
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Investment analysts at HC Wainwright decreased their Q4 2025 earnings per share estimates for shares of Unicycive Therapeutics in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.35) per share for the quarter, down from their previous estimate of $0.50. HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at $1.71 EPS and FY2028 earnings at $6.03 EPS.
Get Unicycive Therapeutics alerts:
UNCY has been the topic of a number of other reports. Benchmark boosted their target price on shares of Unicycive Therapeutics to $21.00 and gave the stock a "speculative buy" rating in a research report on Monday, September 15th. Wall Street Zen raised shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, November 2nd. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Unicycive Therapeutics in a research report on Thursday, October 30th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $34.33.
Check Out Our Latest Analysis on UNCY
Unicycive Therapeutics Stock Up 6.4%
NASDAQ UNCY opened at $5.67 on Monday. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00. The business has a 50 day moving average price of $4.54 and a two-hundred day moving average price of $5.06. The stock has a market cap of $121.85 million, a PE ratio of -1.44 and a beta of 1.87.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.20.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Vivo Capital LLC increased its holdings in shares of Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock valued at $6,537,000 after acquiring an additional 1,400,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Unicycive Therapeutics in the third quarter worth $512,000. Vanguard Group Inc. increased its stake in Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company's stock valued at $2,873,000 after purchasing an additional 52,925 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after purchasing an additional 21,525 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $55,000. Institutional investors and hedge funds own 40.42% of the company's stock.
Unicycive Therapeutics Company Profile
(Get Free Report)Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Further Reading
- Five stocks we like better than Unicycive Therapeutics
- How to Buy Gold Stock and Invest in Gold
- 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
- How to Invest in Small Cap Stocks
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Unicycive Therapeutics Right Now?
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
